Nanoparticles for sustained release of active agents for the treatment of pulmonary hypertension
Pulmonary hypertension is a serious, lifethreatening
disorder which substantially restricts physical capacities and results in a severely reduced life expectancy with an average survival time of only 2.8 years after diagnosis if the disease is not treated.<br> The new nanoparticles now allow a controlled release of inhalable active agents for pulmonary hypertension over a long period of time, thus leading to a prolongation of pharmacological effects and a considerably improved quality of patients' life.
Further Information: PDF
TransMIT Gesellschaft für Technologietransfer mbH
Phone: +49 (0)641/943 64-12
Contact
Dr. Peter Stumpf
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Sea slugs inspire highly stretchable biomedical sensor
USC Viterbi School of Engineering researcher Hangbo Zhao presents findings on highly stretchable and customizable microneedles for application in fields including neuroscience, tissue engineering, and wearable bioelectronics. The revolution in…
Twisting and binding matter waves with photons in a cavity
Precisely measuring the energy states of individual atoms has been a historical challenge for physicists due to atomic recoil. When an atom interacts with a photon, the atom “recoils” in…
Nanotubes, nanoparticles, and antibodies detect tiny amounts of fentanyl
New sensor is six orders of magnitude more sensitive than the next best thing. A research team at Pitt led by Alexander Star, a chemistry professor in the Kenneth P. Dietrich…
